96 related articles for article (PubMed ID: 24330486)
1. Genetic profile and cancer-related pain: a tale from two outlier cases with bone metastatic disease.
Oliveira A; Dinis-Oliveira RJ; Nogueira A; Azevedo AS; Gonçalves F; Silva P; Carvalho F; Medeiros R
Pain Med; 2014 Apr; 15(4):710-2. PubMed ID: 24330486
[No Abstract] [Full Text] [Related]
2. [Genetic variation-- important for the clinical effect of opioids?].
Klepstad P; Dale O; Borchgrevink PC; Kaasa S; Skorpen F
Tidsskr Nor Laegeforen; 2005 Oct; 125(19):2655-8. PubMed ID: 16215614
[TBL] [Abstract][Full Text] [Related]
3. Opioid responsiveness of nociceptive versus mixed pain in clinical cancer patients.
Bechakra M; Moerdijk F; van Rosmalen J; Koch BCP; van der Rijt CCD; Sillevis Smitt PAE; Jongen JLM
Eur J Cancer; 2018 Dec; 105():79-87. PubMed ID: 30439627
[TBL] [Abstract][Full Text] [Related]
4. Combined catechol-O-methyltransferase and mu-opioid receptor gene polymorphisms affect morphine postoperative analgesia and central side effects.
Kolesnikov Y; Gabovits B; Levin A; Voiko E; Veske A
Anesth Analg; 2011 Feb; 112(2):448-53. PubMed ID: 21127283
[TBL] [Abstract][Full Text] [Related]
5. [When morphine does not suffice...].
Zangger P
Rev Med Suisse; 2012 Jan; 8(325):231-2. PubMed ID: 22338530
[No Abstract] [Full Text] [Related]
6. Challenges in interpreting joined allelic combinations of OPRM1 and COMT genes.
Landau R; Ortner C; Carvalho B
Anesth Analg; 2011 Aug; 113(2):432. PubMed ID: 21788333
[No Abstract] [Full Text] [Related]
7. Can heterogeneity of chronic sickle-cell disease pain be explained by genomics? A literature review.
Adegbola MA
Biol Res Nurs; 2009 Jul; 11(1):81-97. PubMed ID: 19487302
[TBL] [Abstract][Full Text] [Related]
8. Role of tapentadol in pain management.
Mendis V
Br J Hosp Med (Lond); 2012 Mar; 73(3):143-7. PubMed ID: 22411644
[No Abstract] [Full Text] [Related]
9. [Genetic polymorphisms and human sensitivity to pain and opioids].
Nishizawa D; Nagashima M; Satoh Y; Tagami M; Ikeda K
Masui; 2009 Sep; 58(9):1093-101. PubMed ID: 19764431
[TBL] [Abstract][Full Text] [Related]
10. Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy.
Hirota T; Ieiri I; Takane H; Sano H; Kawamoto K; Aono H; Yamasaki A; Takeuchi H; Masada M; Shimizu E; Higuchi S; Otsubo K
Drug Metab Dispos; 2003 May; 31(5):677-80. PubMed ID: 12695358
[TBL] [Abstract][Full Text] [Related]
11. Prediction of opioid dose in cancer pain patients using genetic profiling: not yet an option with support vector machine learning.
Olesen AE; Grønlund D; Gram M; Skorpen F; Drewes AM; Klepstad P
BMC Res Notes; 2018 Jan; 11(1):78. PubMed ID: 29374492
[TBL] [Abstract][Full Text] [Related]
12. Environmental and genetic factors associated with morphine response in the postoperative period.
Coulbault L; Beaussier M; Verstuyft C; Weickmans H; Dubert L; Trégouet D; Descot C; Parc Y; Lienhart A; Jaillon P; Becquemont L
Clin Pharmacol Ther; 2006 Apr; 79(4):316-24. PubMed ID: 16580900
[TBL] [Abstract][Full Text] [Related]
13. A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia.
Sia AT; Lim Y; Lim EC; Goh RW; Law HY; Landau R; Teo YY; Tan EC
Anesthesiology; 2008 Sep; 109(3):520-6. PubMed ID: 18719451
[TBL] [Abstract][Full Text] [Related]
14. Genetic variability and clinical efficacy of morphine.
Klepstad P; Dale O; Skorpen F; Borchgrevink PC; Kaasa S
Acta Anaesthesiol Scand; 2005 Aug; 49(7):902-8. PubMed ID: 16045647
[TBL] [Abstract][Full Text] [Related]
15. Long-term rectal administration of high-dose sustained-release morphine tablets.
Walsh D; Tropiano PS
Support Care Cancer; 2002 Nov; 10(8):653-5. PubMed ID: 12436225
[TBL] [Abstract][Full Text] [Related]
16. Expression changes in arrestin β 1 and genetic variation in catechol-O-methyltransferase are biomarkers for the response to morphine treatment in cancer patients.
Matsuoka H; Arao T; Makimura C; Takeda M; Kiyota H; Tsurutani J; Fujita Y; Matsumoto K; Kimura H; Otsuka M; Koyama A; Imamura CK; Tanigawara Y; Yamanaka T; Tanaka K; Nishio K; Nakagawa K
Oncol Rep; 2012 May; 27(5):1393-9. PubMed ID: 22293824
[TBL] [Abstract][Full Text] [Related]
17. Pathobiology and management of prostate cancer-induced bone pain: recent insights and future treatments.
Muralidharan A; Smith MT
Inflammopharmacology; 2013 Oct; 21(5):339-63. PubMed ID: 23918298
[TBL] [Abstract][Full Text] [Related]
18. An opposite-direction modulation of the COMT Val158Met polymorphism on the clinical response to intrathecal morphine and triptans.
Cargnin S; Magnani F; Viana M; Tassorelli C; Mittino D; Cantello R; Sances G; Nappi G; Canonico PL; Genazzani AA; Raffaeli W; Terrazzino S
J Pain; 2013 Oct; 14(10):1097-106. PubMed ID: 23773341
[TBL] [Abstract][Full Text] [Related]
19. Variability in UDP-glucuronosyltransferase genes and morphine metabolism: observations from a cross-sectional multicenter study in advanced cancer patients with pain.
Fladvad T; Klepstad P; Langaas M; Dale O; Kaasa S; Caraceni A; Skorpen F
Pharmacogenet Genomics; 2013 Mar; 23(3):117-26. PubMed ID: 23277092
[TBL] [Abstract][Full Text] [Related]
20. [Local application of strong opioids and wound-related pain].
de la Brière A; Astruc S
Soins; 2011 Nov; (760):21-2. PubMed ID: 22216634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
